Ryan Wiegand
机构: Centers for Disease Control and Prevention
每年引用次数
引用次数
引用: 6,821
H-指数: 47
I10-指数 : 107
出版物: 200
Control and elimination of schistosomiasis as a public health problem thresholds fail to differentiate schistosomiasis morbidity prevalence in children
Fiona M Fleming , Jürg Utzinger , Jürg Utzinger , Ryan E Wiegand
Open Forum Infectious Diseases
2021
Comparison of models for analyzing two-group, cross-sectional data with a Gaussian outcome subject to a detection limit.
Ryan E Wiegand , Charles E Rose , John M Karon
Statistical Methods in Medical Research 25 ( 6) 2733 -2749
7
2016
Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia
Kathrine R Tan , Bonnie L Katalenich , Kimberly E Mace , Michael Nambozi
Malaria Journal 13 ( 1) 227 -227
19
2014
Pooled PCR testing strategy and prevalence estimation of submicroscopic infections using Bayesian latent class models in pregnant women receiving intermittent preventive treatment at Machinga District Hospital, Malawi, 2010.
Zhiyong Zhou , Rebecca Mans Mitchell , Julie Gutman , Ryan E Wiegand
Malaria Journal 13 ( 1) 509 -509
14
2014
Morphologic study of three collagen materials for body wall repair.
Emily E Soiderer , Gary C Lantz , Evelyn A Kazacos , Jason P Hodde
Journal of Surgical Research 118 ( 2) 161 -175
82
2004
Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration
Erica Brook Goodhew , Sheri Maria G Morgan , Andrew J Switzer , Beatriz Munoz
BMC Infectious Diseases 14 ( 1) 216 -216
28
2014
Seroprevalence of Antibodies to Toxocara Species in the United States and Associated Risk Factors, 2011-2014.
Eugene W Liu , Holly M Chastain , Sun Hee Shin , Ryan E Wiegand
Clinical Infectious Diseases 66 ( 2) 206 -212
24
2018
Evaluation of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a retrospective birth outcomes study in Mansa, Zambia.
Kimberly E Mace , Victor Chalwe , Bonnie L Katalenich , Michael Nambozi
Malaria Journal 14 ( 1) 69 -69
20
2015
In vivo efficacy of sulphadoxine-pyrimethamine for the treatment of asymptomatic parasitaemia in pregnant women in Machinga District, Malawi
Julie Gutman , Dyson Mwandama , Ryan E Wiegand , Joseph Abdallah
Malaria Journal 14 ( 1) 197 -197
9
2015
A Persistent Hotspot of Schistosoma mansoni Infection in a Five-Year Randomized Trial of Praziquantel Preventative Chemotherapy Strategies
Ryan E Wiegand , Pauline N M Mwinzi , Susan P Montgomery , YuYen L Chan
The Journal of Infectious Diseases 216 ( 11) 1425 -1433
36
2017
Statistical Analysis of Medical Data Using SAS
Ryan E Wiegand
The American Statistician 60 ( 4) 345 -346
2006
Data Preparation for Analytics Using SAS
Ryan E Wiegand
The American Statistician 62 ( 4) 356 -357
5
2008
Circumcision status and HIV infection among MSM: reanalysis of a Phase III HIV vaccine clinical trial
Deborah A Gust , Ryan E Wiegand , Katrina Kretsinger , Stephanie Sansom
AIDS 24 ( 8) 1135 -1143
31
2010
Ignoring the group in group-level HIV/AIDS intervention trials: a review of reported design and analytic methods.
Sherri L Pals , Ryan E Wiegand , David M Murray
AIDS 25 ( 7) 989 -996
8
2011
Understanding disparities in HIV infection between black and white MSM in the United States.
Alexandra M Oster , Ryan E Wiegand , Catlainn Sionean , Isa J Miles
AIDS 25 ( 8) 1103 -1112
144
2011
Introductory Econometrics: Using Monte Carlo Simulation With Microsoft Excel
Ryan E Wiegand
Journal of the American Statistical Association 101 ( 476) 1730 -1731
12
2006
HIV testing outside of the study among men who have sex with men participating in an HIV vaccine efficacy trial.
Deborah A Gust , Ryan E Wiegand , Michael Para , Robert T Chen
Journal of Acquired Immune Deficiency Syndromes 52 ( 2) 294 -298
6
2009
Development of a multiplex bead assay to detect immunoglobulin G antibodies to Babesia duncani in human serum
Yong Wang , TaLesa Aderohunmu , Henry Bishop , Isabel McAuliffe
Journal of Clinical Microbiology 59 ( 11) 10 -1128
1
2021
Preliminary estimates of effectiveness of monovalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection among children aged 3--5 years—Increasing Community Access to Testing program, United States, July 2022--February 2023
Katherine E Fleming-Dutra , Allison Avrich Ciesla , Lauren E Roper , Zachary R Smith
Morbidity and Mortality Weekly Report 72 ( 7) 177
2023
Early Estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA. 5--and XBB/XBB. 1.5--related sublineages among immunocompetent adults—Increasing Community Access to Testing Program, United States, December 2022--January 2023
Ruth Link-Gelles , Allison Avrich Ciesla , Lauren E Roper , Heather M Scobie
Morbidity and Mortality Weekly Report 72 ( 5) 119
4
2023